Vetter Serializes the First Product for South Korea
Vetter has announced the manufacture of the first commercial batches with single-use identification numbers. Following the introduction of a comprehensive serialization service last year, the company has now implemented product serialization for secondary packaging for one of the world's leading pharmaceutical companies. In accordance with the requirements from the South Korean Ministry of Food and Drug Safety (MFDS) Vetter's solution identifies the drugs on the folding boxes via a 2D data matrix code with a serial number, GTIN, expiry date and batch number.
As the number of counterfeit drugs continues to grow, regulatory authorities around the world are increasingly relying on clear identification of products through serialization. They are demanding that the smallest packaging unit be marked with a single-use identification number. South Korea is among those countries requiring serialization with an aim towards protecting against counterfeiting, as well as a more secure supply chain.
"Together with our customer, we prepared for these requirements very early on," says Thomas Otto, managing director at Vetter. "We have been active in filling and final packaging for the company for years. Thanks to our serialization service, our partner can now meet the regulatory requirements for South Korea. We are, however, also aware of the fact that regulatory requirements differ from one country to the next. Therefore, we offer pharma and biotech companies a wide range of options that will give them flexibility when reacting to different regulatory standards."
Presently, South Korea has only asked for serialization on the folding package. China, however, has legislated use of 1D linear codes including aggregation with the shipping box. As such, Vetter provides a broad variety of services in secondary packaging, primary packaging and final assembly that give its customers a great deal of flexibility to accommodate various regulatory or market needs. The company's comprehensive serialization service includes a range of formats for serial numbers, different code systems; such as a 2D data matrix codes, interfaces and reports, as well as various aggregation depths.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.